Literature DB >> 21163539

Cognitive dysfunction in drug induced parkinsonism (DIP).

Young-Do Kim1, Joong-Seok Kim, Sung-Woo Chung, In-Uk Song, Dong-Won Yang, Yun-Jung Hong, Yeong-In Kim, Kook-Jin Ahn, Hee-Tae Kim, Kwang-Soo Lee.   

Abstract

Several studies have suggested that the presence of dementia increases the risk of developing DIP. However, these prior studies exclusively focused on the underlying conditions before the development of DIP and there are no studies about the characteristics and prognosis of the cognitive status associated with DIP. We investigate the cognitive impairments associated with DIP by comparing neuro-psychological test results in patients with Parkinson's disease (PD) and normal controls and the longitudinal outcome of cognition in DIP. The cohort in this study included 13 consecutive patients with DIP and 91 patients with PD; all subjects completed a clinical assessment, neuropsychological investigation, and magnetic resonance imaging of brain. All patients with DIP were followed closely for more than six months after withdrawal of the offending drug. The cognitive function in DIP was significantly worse than in controls for most domains; however, there were no significant differences found in the comparisons with the PD patients. In addition, the severity of motor impairment was in part associated with cognitive function. Some patients had transient and reversible cognitive impairment, similar to other Parkinsonian motor features, and others experienced persistence and eventual worsening of their cognitive dysfunction after discontinuation of the offending drug. The results of this study suggest that cognitive impairment in patients with DIP reflects the toxic/metabolic symptoms associated with the offending drug in addition to being a risk factor for DIP.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21163539     DOI: 10.1016/j.archger.2010.11.025

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  7 in total

Review 1.  Drug-induced parkinsonism in the elderly: incidence, management and prevention.

Authors:  José Luis López-Sendón; María Angeles Mena; Justo García de Yébenes
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

2.  Microstructural white matter alterations in patients with drug induced parkinsonism.

Authors:  Yoonju Lee; Yong Ho Choi; Jae Jung Lee; Hye Sun Lee; Young H Sohn; Jong-Min Lee; Phil Hyu Lee
Journal:  Hum Brain Mapp       Date:  2017-09-12       Impact factor: 5.038

3.  Neurologists' diagnostic accuracy of depression and cognitive problems in patients with parkinsonism.

Authors:  Angela E P Bouwmans; Wim E J Weber
Journal:  BMC Neurol       Date:  2012-06-15       Impact factor: 2.474

4.  Cardiovascular Autonomic Dysfunction in Patients with Drug-Induced Parkinsonism.

Authors:  Joong Seok Kim; Dong Woo Ryu; Ju Hee Oh; Yang Hyun Lee; Sung Jin Park; Kipyung Jeon; Jong Yun Lee; Seong Hee Ho; Jungmin So; Jin Hee Im; Kwang Soo Lee
Journal:  J Clin Neurol       Date:  2016-10-07       Impact factor: 3.077

5.  Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients.

Authors:  Lydia E Pieters; P Roberto Bakker; Peter N van Harten
Journal:  Front Psychiatry       Date:  2018-02-05       Impact factor: 4.157

6.  Proxy WHO Disability Assessment Schedule 2.0 Is Clinically Useful for Assessing Psychosocial Functioning in Severe Mental Illness.

Authors:  Anne B Koopmans; Daphne van Hoeken; Diana E Clarke; David J Vinkers; Peter N van Harten; Hans W Hoek
Journal:  Front Psychiatry       Date:  2020-04-15       Impact factor: 4.157

7.  Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics.

Authors:  Hyun Jung Ahn; Woo-Kyoung Yoo; Jaeseol Park; Hyeo-Il Ma; Yun Joong Kim
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.